Chagas Disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. About 6 million to 7 million people worldwide are estimated to be infected with T. cruzi, the parasite that causes Chagas disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as ‘kissing bugs’, among many other popular names, depending on the geographical area.
DelveInsight’s, “Chagas disease Pipeline Insight, 2021” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of Chagas Disease Companies are:
- Seren pharmaceuticals
- Collaborations Pharmaceuticals
- ConserV Bioscience
- Eisai Co Ltd
- And Many Others
Request for free Sample Report: https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight
DelveInsight’s Chagas disease Report covers around 4+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Some of Chagas Disease therapies are:
- Fosravuconazole
- Pyronaridine
- Chagas disease vaccine
- Research programme: Chagas disease therapeutics
- And Many Others
Request for free Sample Report: https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight
Current Chagas Disease Treatment Scenario and Chagas Disease Emerging Therapies:
- How many companies are developing Chagas disease drugs?
- How many Chagas disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chagas disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chagas disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for free Sample Report: https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Chagas disease: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Chagas disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chagas disease Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Fosravuconazole: Seren Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Chagas disease vaccine: ConserV Bioscience
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Chagas disease Key Companies
Chagas disease Key Products
Chagas disease- Unmet Needs
Chagas disease- Market Drivers and Barriers
Chagas disease- Future Perspectives and Conclusion
Chagas disease Analyst Views
Chagas disease Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chagas-disease-pipeline-insight